Publication and Public Disclosure Sample Clauses

Publication and Public Disclosure. In accordance with the requirements of this Section 9 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 9.2), “Confidentiality of Unpublished Data” (Section 9.3)), Institution and Investigator shall have the right to publish or present their Study data following from their own activities conducted under this Agreement. Any proposed publication or presentation shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Study Results first after the primary source publication of the Sponsor is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Sponsor’s Head of Global Medical Publication, email address: for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within sixty (60) days of its receipt, Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (other than Study Results) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution and/or Investigator, as applicable, to remove specifically identified Confidential Information (other than Study Results) and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for Inventions.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Publication and Public Disclosure. In accordance with the requirements of this Section 5 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Site Study results following from Site’s own activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Site Study Data first after the primary source publication of the Sponsor is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Sponsor’s Head of Global Medical Publication, email address: dokumenty důvodně Zadavatelem požadované za účelem ochrany a zajištění vlastnických práv Zadavatele k Objevům. 4.4
Sample 1
Publication and Public Disclosure. In accordance with the requirements of this Section 5 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Site Study results following from Site’s own activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) poprvé do praxe či jakkoli jinak vynalezeny či rozvinuty Poskytovatelem, Zkoušejícím či jakýmkoli jejich zaměstnancem či členem personálu v souvislosti s prováděním Studie.
Sample 1
Publication and Public Disclosure. 5.1 Publikování a zveřejnění In accordance with the requirements of this Section 5 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Site Study results following from Site’s own activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Site Study Data first after the primary source publication of the Company is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Company’s Head of Global Medical Publication, email address: XxxxxxxXxxxxxxxxxxxx@xxxxxxxxxx.xxx for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within sixty (60) days of its receipt, Company shall advise MS700568_0213 Country: Czech Republic Site No. 602 _PI Name_ Institution name Faculty of Hospital Ostrava Merck_NIS_INST_INV_Agrm_19May2023_From_Merck_Global_ NIS_v1.0_17May2023 Page 16 of 42 V souladu s požadavky tohoto článku 5 (například časová omezení u „Multicentrických publikací“ (článek 5.2), „Důvěrnost nepublikovaných údajů" (článek 5.3)) budou mít Zdravotnické zařízení a Zkoušející právo publikovat nebo prezentovat Výsledky klinického hodnocení dosažené v Místě provádění klinického hodnocení, které vyplývají z vlastních aktivit Místa provádění klinického hodnocení prováděných v rámci této Smlouvy. Veškeré publikace nebo prezentace navrhované Místem provádění klinického hodnocení musejí být v souladu s odbornými standardy, a to tak, že budou (i) uplatňovat nejvyšší standardy v oboru, například správnou publikační praxi a doporučení pro provádění, vykazování, úpravu a zveřejňování vědeckých prací v lékařských časopisech od Mezinárodního výboru vydavatelů lékařských časopisů (ICMJE) v aktuální verzi a (ii) publikovat Údaje ze Studie z Místa provádění klinického hodnocení až poté, co Společnost zveřejní primární zdrojovou publikaci. Kromě toho Zdravo...
Sample 1
Publication and Public Disclosure. In accordance with the requirements of this Section 5 (including but not limited to the time- restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Study results following from activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Institution´s Study Data first after the primary source publication of the Sponsor is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Sponsor’s Head zastoupení svých zaměstnanců, převede na Zadavatele (nebo přidružený subjekt jmenovaný Zadavatelem) veškerá svá práva, nároky a zájmy k Objevům, včetně všech patentů, autorských děl a jiných práv duševního vlastnictví k tomuto se vztahujícím, jakož i veškerá práva procesní povahy a nároky na náhrady škod a užitky, jež již vznikly v důsledku minulého či současného porušení shora uvedených práv. Poskytovatel se zavazuje, že bude náležitě spolupracovat a poskytne Zadavateli součinnost při vyhotovení a uzavření, a zajistí, že její zaměstnanci vyhotoví a uzavřou, veškeré dokumenty důvodně Zadavatelem požadované za účelem ochrany a zajištění vlastnických práv Zadavatele (nebo přidruženého subjektu jmenovaného Zadavatelem) k
Sample 1
Publication and Public Disclosure. Publication and public disclosure of scientific information shall be governed by Section 3.8 of the MTF processing Agreement.
Sample 1

Related to Publication and Public Disclosure

  • No Public Disclosure The Company shall not disclose any holder of Investor Units’ name or identity as an investor in the Company in any press release or other public announcement or in any document or material filed with any governmental entity, without the prior written consent of such Person, unless such disclosure is required by applicable law or governmental regulations or by order of a court of competent jurisdiction, in which case prior to making such disclosure the Company shall give written notice to such Person describing in reasonable detail the proposed content of such disclosure and shall permit such Person to review and comment upon the form and substance of such disclosure.

  • Review of Public Disclosures All SEC filings (including, without limitation, all filings required under the Exchange Act, which include Forms 10-Q and 10-QSB, 10-K and 10K-SB, 8-K, etc) and other public disclosures made by the Company, including, without limitation, all press releases, investor relations materials, and scripts of analysts meetings and calls, shall be reviewed and approved for release by the Company’s attorneys and, if containing financial information, the Company’s independent certified public accountants.

  • Press Releases and Public Announcements No Party shall issue any press release or make any public announcement relating to the subject matter of this Agreement without the prior written approval of the other Party; provided, however, that any Party may make any public disclosure it believes in good faith is required by applicable law or any listing or trading agreement concerning its publicly-traded securities (in which case the disclosing Party will use its reasonable best efforts to advise the other Party prior to making the disclosure).

  • Public Disclosures The Company shall not, nor shall it permit any Subsidiary to, disclose any Investor’s name or identity as an investor in the Company in any press release or other public announcement or in any document or material filed with any governmental entity (other than tax filings in the ordinary course), without the prior written consent of such Investor, unless such disclosure is required by applicable law or governmental regulations or by order of a court of competent jurisdiction, in which case prior to making such disclosure the Company shall give written notice to such Investor describing in reasonable detail the proposed content of such disclosure and shall permit such Investor to review and comment upon the form and substance of such disclosure.

  • Public Disclosure Unless otherwise required by law, prior to the ----------------- Effective Time, no disclosure (whether or not in response to an inquiry) of the subject matter of this Agreement shall be made by any party hereto unless approved by Parent and the Company prior to release, provided that such approval shall not be unreasonably withheld.

  • Publications and Public Statements I will obtain the Company’s written approval before publishing or submitting for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information. To ensure that the Company delivers a consistent message about its products, services and operations to the public, and further in recognition that even positive statements may have a detrimental effect on the Company in certain securities transactions and other contexts, any statement about the Company which I create, publish or post during my period of employment and for six (6) months thereafter, on any media accessible by the public, including but not limited to electronic bulletin boards and Internet-based chat rooms, must first be reviewed and approved by an officer of the Company before it is released in the public domain.

  • Confidentiality and Public Announcements The parties recognize that successful consummation of the transactions contemplated by this Agreement may be dependent upon confidentiality with respect to the matters referred to herein. In this connection, pending public disclosure thereof, each of the parties hereto severally and not jointly agrees not to disclose or discuss such matters with anyone not a party to this Agreement (other than its counsel, advisors, corporate parents and affiliates) without the prior written consent of the other parties hereto, except for filings required pursuant to the Exchange Act and the rules and regulations thereunder or disclosures its counsel advises are necessary in order to fulfill its obligations imposed by law or the requirements of any securities exchange. At all times during the term of this Agreement, the parties hereto will consult with each other before issuing or making any reports, statements or releases to the public with respect to this Agreement or the transactions contemplated hereby and will use good faith efforts to agree on the text of public reports, statements or releases.

  • Prohibition on Press Releases and Public Announcements The Company shall not issue press releases or engage in any other publicity, without the Representative’s prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1st) Business Day following the forty-fifth (45th) day after the Closing Date, other than normal and customary releases issued in the ordinary course of the Company’s business.

  • Confidentiality and Publication Subject to the remaining provisions of this clause 8, each Party will treat all Confidential Information of any other Party as confidential and will not, without the consent of the other relevant Party, disclose or permit the same either to be disclosed to third parties or to be used, except solely as contemplated by this Agreement. Each Party must use all reasonable endeavours to ensure that its representatives comply with the obligations of confidentiality imposed upon it under this clause 8 as if those representatives were bound in the same way. Each Party must advise each other Party as soon as practicably possible of any breach of any confidentiality obligations under this Agreement of which it becomes aware. A Party may disclose Confidential Information if required to do so by law or to its professional advisers, subject to the relevant adviser being bound by similar obligations of confidentiality, or if necessary, entering into an appropriate confidentiality undertaking. A Party may publish the Project IP, subject to it complying with the following: prior to any publication, the Party must provide the other Party with full details of the Project IP it proposes to publish and the nature of the publication; and the other Party must notify the first Party whether permission to publish has been granted or refused within 30 days of the request (or such other period as may be set out at Item 7 of the Schedule) (Period); and if the other Party fails to notify the first Party of its decision under clause 8.5(b) within the Period shall be deemed to have consented to the proposed publication by the first Party; and any other Party may only refuse a request to publish if, in that other Party’s reasonable opinion, the publication is likely to jeopardise: the protection of Project IP (as applicable) under any statute of monopoly; or the successful commercialisation of the Project IP by the Party with such rights, or

  • Confidentiality; Public Disclosure Each of the parties hereto hereby agrees that the information obtained pursuant to the negotiation and execution of this Agreement shall be treated as confidential and not be disclosed to third parties who are not agents of one of the Parties to this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.